Lin Lei

Lin Lei

Auto-generated profile, based on publicly available information

Lin Lei

Department of Clinical Laboratory Medicine, Xi'an Hospital of Traditional Chinese Medicine, Xi’an, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
LYLijuan Yu
Lijuan Yu
BSBing-Dong Sui
Bing-Dong Sui
WFWeixiao Fan
Weixiao Fan
LLLin Lei
Lin Lei
LZLei Zhou
Lei Zhou
XHXiaoke Hao
Xiaoke Hao
In patients with prostate cancer (PCa), bone lesions appear osteoblastic in radiographs; however, pathological fractures frequently occur in PCa patients, and bone resorption is observed in all metastatic lesions under histopathologic assessment. The mechanisms that balance the activities of osteoblasts and osteoclasts in PCa patients remain unclear. We unexpectedly discovered that PCa exosomes are critical mediators in the regulation of bone homeostasis that results in osteoclastic lesions and thereby promotes tumor growth in bone. We evaluated how exosomes derived from osteoblastic, osteoclastic, and mixed PCa cell lines affect osteoblast and osteoclast differentiation, revealing that all three types of PCa exosomes promoted osteoclastogenesis in vitro and induced osteolysis in vivo. Mechanistically, microRNAs (miRNAs) delivered by PCa exosomes were found to play several key roles in bone homeostasis. Among the delivered miRNAs, miR‐92a‐1‐5p, the most abundant miRNA, downregulated type I collagen expression by directly targeting COL1A1, and thus promoting osteoclast differentiation and inhibiting osteoblastogenesis. Furthermore, PCa exosomes also markedly reduced type I collagen expression in vivo. Our findings not only offer a novel perspective on tumor bone metastasis, where—contrary to our initial hypothesis—exosomes derived from an osteoblastic tumor induce osteoclast differentiation, but also suggest potential therapeutic targets for PCa bone metastasis.

6 December 2022 in Heliyon
Verified
Journal Article
Open access
LLLin Lei
Lin Lei
LYLijuan Yu
Lijuan Yu
WFWeixiao Fan
Weixiao Fan
XHXiaoke Hao
Xiaoke Hao
Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer (PCa). However, after 2–3 years ADT treatment, prostate cancer inevitably transits from androgen-dependent PCa (ADPC) to androgen-independent PCa (AIPC), which has a poor prognosis owing to its unclear mechanism and lack of effective therapeutic targets. Small extracellular vesicles (sEVs) play a vital role in the development of cancer. However, the role of PCa sEVs in the transformation of AIPC remains poorly understood. Two different cell models were employed and compared. sEVs from ADPC cells (LNCaP) and AIPC cells (LNCaP-AI + F cells) were isolated and characterized. After co-culture of LNCaP-AI + F sEVs with LNCaP cells and of LNCaP sEVs with LNCaP-AI + F cells, androgen-independent transformation was determined respectively. Mechanically, small RNA sequencing was performed. Androgen-independent transformation was examined by the upregulation and downregulation of miRNA and downstream pathways were analyzed. LNCaP-AI + F sEVs promoted the androgen-independent transformation of LNCaP cells. Interestingly, LNCaP sEVs exhibited a capacity to reverse the process.Let-7a-5p transfer was demonstrated. Furthermore, let-7a-5p overexpression promotes the androgen-independent transformation and let-7a-5p down-regulation reverses the process. Androgen receptor (AR) and PI3K/Akt pathways were identified and demonstrated by both let-7a-5p regulation and PCa sEVs coculture. PCa sEVs are intimately involved in the regulation of androgen-independent transformation of prostate cancer by transferring the key sEVs molecular let-7a-5p and then activating the AR and PI3K/Akt signaling pathways. Our results provide new perspectives for the development of sEVs and sEVs molecular targeted treatment approaches for AIPC patients.

11 June 2025 in Research Square
Verified
Preprint
Open access
PDF file
ZLZhuo Li
Zhuo Li
JZjian zhou
jian zhou
YRYingjie Ren
Yingjie Ren
LLLin Lei
Lin Lei
XWXin Wang
Xin Wang
LYLijuan Yu
Lijuan Yu
In children, Epstein-Barr Virus (EBV) often causes infectious mononucleosis (EBV-IM) but can escalate to a severe condition called EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Differentiating these conditions is vital for proper treatment and prognosis. This study aimed to find plasma biomarkers to distinguish between EBV-IM and EBV-HLH. A retrospective analysis was performed on 17 children with EBV-IM and 23 with EBV-HLH. Selected microRNAs (miRNAs) were measured in plasma using qPCR, and EBV DNA was isolated and quantified. Biomarker effectiveness was assessed using constructing receiver operating characteristic (ROC) curves and the area under the curve (AUC) calculations. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed a significant enrichment of miR-375, miR-148a-3p, and miR-92a-1-5p within the Viral Carcinogenesis pathway. Quantitative PCR validation demonstrated a marked upregulation of miR-375 and miR-148a-3p in patients with EBV-HLH compared to those with EBV-IM, whereas the expression of miR-92a-1-5p did not show a statistically significant difference between the groups. Notably, receiver operating characteristic (ROC) analysis indicated that the combined evaluation of miR-375 and EBV-DNA load achieved superior diagnostic discrimination between EBV-HLH and EBV-IM, with an AUC of 0.951, highlighting its potential high clinical utility. The integrated biomarker panel, consisting of miR-375 and EBV-DNA load, demonstrated high diagnostic accuracy in distinguishing between EBV-HLH and EBV-IM. These findings offer a clinically applicable tool for precise differential diagnosis and therapeutic stratification.